Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin

Australasian Journal of Dermatology

Volumn 40, Issue 3, 1999, Pages 153-157

  Phan, Tri G ^a   Wong, Richard C W ^a   Crotty, Kerry ^a   Adelstein, Stephen ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cutaneous drug reaction; Fas mediated apoptosis; Gamma delta T cells; Neutralizing antibodies; Nevirapine

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CEFAZOLIN; FLUCONAZOLE; GAMMA INTERFERON; IMMUNOGLOBULIN G; NERVE GROWTH FACTOR; NEUTRALIZING ANTIBODY; NEVIRAPINE; RITONAVIR; SAQUINAVIR; SULFAMETHOXAZOLE; SUPERANTIGEN; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL SUPERINFECTION; CASE REPORT; CAUSE OF DEATH; CELL COUNT; CORTICOSTEROID THERAPY; DRUG TOLERANCE; ERYTHEMA MULTIFORME; FEVER; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; INCIDENCE; MALE; PANCYTOPENIA; PATHOPHYSIOLOGY; RASH; RISK ASSESSMENT; SKIN BIOPSY; SKIN ULCER; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; NEVIRAPINE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REVERSE TRANSCRIPTASE INHIBITORS; SKIN; TREATMENT OUTCOME;

EID: 0032815919     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.1999.00347.x     Document Type: Article

References (25)

1. 1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch. Dermatol. 1993; 129: 92-6.
2. 2. Rzany B, Mockenhaupt M, Stocker U, Hamonda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch. Dermatol. 1993; 129: 1059.
3. 3. van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW. Adverse reactions to co-trimazole in IIIV infection. Lancet 1991; 338: 431-3.
4. 4. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J. Am. Acad. Dermatol. 1992; 26: 567-74.
5. 5. Chosidow O, Bourgault L, Roujeau JC. Drug rashes: What are the targets of cell-mediated cytotoxicity? Arch. Dermatol. 1994; 130: 627-9.
6. 6. Garat H, el Sayed F, Obadia M, Bazex J. Erythema multiforme caused by saquinavir. Ann. Dermatol. Venereol. 1998; 125: 42-3.
7. 7. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1992; 5: 1237-57.
8. 8. Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998; 351; 567.
9. 9. Revuz J, Penso D, Roujeau JC et al. Toxic epidermal necrolysis: Clinical findings and prognostic factors in 87 patients. Arch. Dermatol. 1987; 123: 1160-5.
10. 10. Halebian PH, Corder VJ, Madden MR, Finkelstein JL, Shires GT. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann. Surg. 1986; 204: 503-12.
11. 11. Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch. Dermatol. 1991; 127: 740-1.
12. 12. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourello O, Ioannides D, Papkonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int. J. Dermatol. 1997; 36: 218-21.
13. 13. Sullivan JR, Watson A. Lamotrigine induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management. Australas. J. Dermatol. 1996; 37: 208-12.
14. 14. Amato GM, Travia A, Ziino O. The use of intravenous high-dose immunoglobulins (IVIG) in a case of Stevens-Johnson syndrome. Pediatr. Med. Chir. 1992; 14: 555-6.
15. 15. Moudgil A, Poral S, Brunnel P, Jordan SC. Treatment of Stevens-Johnson syndrome with pooled human intravenous immune globulin. Clin. Pediatr. Phila. 1995; 34: 48-51.
16. 16. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J. Allergy Clin. Immunol. 1996; 98: 1112-15.
17. 17. Barry W, Hudgins, L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267: 3315-16.
18. 18. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigen. J. Clin. Invest. 1993; 91: 602-7.
19. 19. Paul C, Wolkenstein P, Adle H et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol. 1996; 134: 710-14.
20. 20. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Pierard GE. Macrophages and tumour necrosis factor α in toxic epidermal necrolysis. Arch. Dermatol. 1994; 130: 605-8.
21. 21. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch. Dermatol. 1997; 133: 845-9.
22. 22. Sayama K, Yonehara S, Watanabe Y, Miki Y. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J. Invest. Dermatol. 1994; 103: 330-4.
23. 23. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
24. 24. Libero GD. Sentinel function of broadly reactive human γδ T cells. Immunol. Today 1997; 18: 22-6.
25. 25.Mak TW, Ferrick DA. The γδ T cell bridge: Linking innate and acquired immunity. Nat. Med. 1998; 4: 764-5.